News

InBio and Beckman Coulter Partner to Advance Food Allergy Diagnostics

InBio, a global leader in high-quality, purified allergen proteins, and Beckman Coulter Life Sciences, a Danaher company and a global leader in laboratory automation and innovation, are collaborating to enhance the performance of basophil activation tests (BAT) for food allergy research. The collaboration integrates InBio’s Food Protein Standards and purified allergens with the Next-Generation Basophil Activation Test (BAT) platform from Beckman Coulter Life Sciences.

InBio’s Food Protein Standards and purified allergen components are potent, biologically active proteins derived from foods such as peanut, egg, milk, tree nuts, and shellfish. These reagents are a critical component for BAT tests, and are validated for immunological consistency, ensuring reproducibility in high-sensitivity assays.

The Next-Generation BAT* by Beckman Coulter Life Sciences is a research use only breakthrough in functional allergy testing that offers researchers a powerful tool to assess allergic sensitization and reactivity with greater precision. Leveraging advanced flow cytometry and automation to measure basophil activation in response to allergen exposure, the Next-Generation BAT is an in vitro alternative to oral food challenges. The integration of InBio’s food proteins ensures consistency in allergen stimulation, reducing variability and improving test interpretation.

The Next-Generation BAT powered by InBio allergens can test for multiple allergens at once through a blood draw — saving hours of food testing and exposure to potentially harmful reactions.

Read more here.

Recent News

06/02/2026

TearSolutions Receives FDA Orphan Drug and Fast Track Designations for Lacripep® in Neurotrophic Keratitis and Initiates Phase 2 Clinical Trial with First Patients Dosed

TearSolutions, Inc. (“TearSolutions”), a clinical-stage biotechnology company developing novel ophthalmic therapeutics, today announced receiving Food and Drug Administration (FDA) Orphan Drug (ODD) and Fast Track Designations for Lacripep in Neurotrophic Keratitis (NK) and initiating a Phase 2 clinical trial with first patients dosed. The FDA’s ODD provides incentives, including tax credits for clinical testing and

06/02/2026

Contraline Announces $92.5 Million Series B Financing to Advance NES/T Male Contraceptive into Late-Stage Development

Contraline, Inc., a clinical-stage biopharmaceutical company developing novel male contraceptives, today announced the closing of a $92.5 million Series B financing co-led by BVF Partners L.P. and RA Capital Management, with participation from GV (Google Ventures), Lumira Ventures, Invus, and other new and existing investors. In conjunction with the closing of the Series B financing,

06/02/2026

GEN Names BioHealth Capital Region a Top 3 U.S. Biopharma Cluster for Fourth Year in a Row

The BioHealth Capital Region, spanning Maryland, Virginia, and Washington, D.C., has once again been named one of the nation’s Top 3 biopharma clusters by Genetic Engineering & Biotechnology News (GEN), marking the region’s fourth consecutive year in the Top 3. GEN’s 2026 “Top 10 U.S. Biopharma Clusters” ranking was authored by Alex Philippidis, Senior Business